Desoximetasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Desoximetasone: From Inflammatory Skin Conditions to Alopecia Areata
One-Sentence Summary
Desoximetasone is a potent topical corticosteroid, originally used for inflammatory skin conditions such as atopic dermatitis, contact dermatitis, seborrheic dermatitis and discoid lupus erythematosus. The TxGNN model predicts it may be effective for alopecia areata, with 1 randomized, double-blind, placebo-controlled trial publication and no registered clinical trials currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory skin conditions (e.g., atopic dermatitis, contact dermatitis, seborrheic dermatitis, discoid lupus erythematosus). Approved indication text was not available on the India licences. |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data |
| Number of Listed Products | 4 (valid: 4) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, desoximetasone is a potent topical corticosteroid that acts on the glucocorticoid receptor (NR3C1). It is used to reduce skin inflammation from allergic reactions, eczema and psoriasis.
Alopecia areata is an autoimmune condition in which T-cell-mediated attack on hair follicles causes hair loss. Desoximetasone is already used in several immune-mediated and inflammatory skin diseases, including primary cutaneous T-cell lymphoma and discoid lupus erythematosus. Local glucocorticoid-mediated suppression of inflammation around the follicle is therefore mechanistically plausible, and topical corticosteroids are already used for this condition.
The one identified study is a randomized, double-blind, placebo-controlled trial of 0.25% desoximetasone cream in alopecia areata. Its abstract was not available, so the outcome is not confirmed here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11030789 | 2000 | RCT | Archives of Dermatology | Randomized, double-blind, placebo-controlled trial of 0.25% desoximetasone cream in alopecia areata (abstract not available; outcome not confirmed) |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 244552 | Xinasone HP Cream (Lupin Ltd) | Tube of 15 gm cream | Not specified |
| 174397 | Provate-D Cream (Percos India Pvt Ltd) | Tube of 15 gm cream | Not specified |
| 60538 | Dexomet Cream (Sun Pharmaceutical Industries Ltd) | Tube of 15 gm cream | Not specified |
| 72679 | Emcor Cream (Emcure Pharmaceuticals Ltd) | Packet of 15 gm cream | Not specified |
Safety Considerations
- Contraindications (from TxGNN model (deep learning) associations, not label text): The drug-disease contraindication links come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. They include pituitary hormone deficiencies (e.g., hypopituitarism, growth hormone deficiency, hypogonadotropic hypogonadism, Kallmann syndrome, Sheehan syndrome), thymus gland disease, skin atrophy, and peripheral vascular disease (peripheral arterial disease, intermittent claudication). Skin atrophy is particularly relevant to prolonged topical use.
- Drug Interactions: Only a pharmacological target association was identified (glucocorticoid receptor, NR3C1). No specific drug-drug interactions were reported.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A randomized, double-blind, placebo-controlled trial of desoximetasone in alopecia areata exists, the drug class is already used for this condition, and the drug is marketed in India as a topical cream. However, the trial outcome is unconfirmed and there are no registered trials, so this is best treated as a research question rather than a ready indication.
To proceed, the following is needed:
- Full text or abstract of PMID 11030789 to confirm efficacy and safety results
- Package insert warnings and contraindications for the Indian products
- Detailed mechanism of action data
- Assessment of skin atrophy risk and the application duration and site limits for scalp use
- Confirmation of the approved indications on the Indian licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.